The one-shot regimen of Convidecia has been authorized for use in eight countries, including China, Malaysia, Mexico, Pakistan, Chile, Ecuador, Argentina and Hungary.
One participant who only received one CoronaVac dose but was randomized to receive a heterologous booster dose of Convidecia in group A was reclassified into group C.
Study design and analysis set Between May 25 and 26, 2021, we recruited 302 participants aged between 18 and 75 years who had received one dose of CoronaVac in the past 1—3 months or two doses of CoronaVac in the past 3—6 months.